MY138334A - Imidazole derivatives - Google Patents
Imidazole derivativesInfo
- Publication number
- MY138334A MY138334A MYPI20020294A MYPI20020294A MY138334A MY 138334 A MY138334 A MY 138334A MY PI20020294 A MYPI20020294 A MY PI20020294A MY PI20020294 A MYPI20020294 A MY PI20020294A MY 138334 A MY138334 A MY 138334A
- Authority
- MY
- Malaysia
- Prior art keywords
- imidazole derivatives
- compounds
- receptor
- key
- ens
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01101947 | 2001-01-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY138334A true MY138334A (en) | 2009-05-29 |
Family
ID=8176317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI20020294A MY138334A (en) | 2001-01-29 | 2002-01-25 | Imidazole derivatives |
Country Status (23)
| Country | Link |
|---|---|
| US (3) | US6610723B2 (enExample) |
| EP (1) | EP1358165B1 (enExample) |
| JP (1) | JP4094956B2 (enExample) |
| KR (1) | KR100619106B1 (enExample) |
| CN (2) | CN101798298B (enExample) |
| AR (1) | AR035422A1 (enExample) |
| AT (1) | ATE425147T1 (enExample) |
| BR (1) | BR0206758A (enExample) |
| CA (1) | CA2434813C (enExample) |
| CY (1) | CY1110265T1 (enExample) |
| DE (1) | DE60231477D1 (enExample) |
| DK (1) | DK1358165T3 (enExample) |
| ES (1) | ES2319967T3 (enExample) |
| GC (1) | GC0000318A (enExample) |
| GT (1) | GT200200013A (enExample) |
| JO (1) | JO2292B1 (enExample) |
| MX (1) | MXPA03006773A (enExample) |
| MY (1) | MY138334A (enExample) |
| PA (1) | PA8537801A1 (enExample) |
| PE (1) | PE20020917A1 (enExample) |
| PT (1) | PT1358165E (enExample) |
| WO (1) | WO2002060877A1 (enExample) |
| ZA (1) | ZA200305626B (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005531548A (ja) * | 2002-05-02 | 2005-10-20 | ニューロジェン コーポレイション | 置換イミダゾール誘導体：ｇａｂａａ受容体リガンド |
| WO2005028467A1 (en) | 2003-09-15 | 2005-03-31 | Anadys Pharmaceuticals, Inc. | Antibacterial 3,5-diaminopiperidine-substitute aromatic and heteroaromatic compounds |
| MXPA06014909A (es) | 2004-06-18 | 2007-02-28 | Chiron Corp | Derivados de n-(1-(1-bencil -4-fenil-1h -imidazol -2-il)-2, 2-dimetilpropil) benzamida y compuestos relacionados como inhibidores de proteina de huso de cinesina (ksp) para el tratamiento del cancer. |
| ITRM20050094A1 (it) * | 2005-03-04 | 2006-09-05 | Univ Siena | Derivati del 1-(1,5-di(4-clorofenil)-2metil-1h-3-pirroli)metil)-4-metilpiperazina (bm 212), procedimento per la loro produzione e uso di essi come antitubercolari. |
| EP1940822A1 (en) | 2005-10-14 | 2008-07-09 | NeuroSearch A/S | Imidazole derivatives and their use for modulating the gaba-a receptor complex |
| KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
| JP5492075B2 (ja) * | 2007-05-23 | 2014-05-14 | アラーガン インコーポレイテッド | アドレナリンレセプター作用薬としての（（二環式ヘテロアリール）イミダゾリル）メチルヘテロアリール化合物 |
| WO2010009327A1 (en) | 2008-07-17 | 2010-01-21 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Compounds for the treatment of pathologies associated with aging and degenerative disorders |
| BRPI0916576A2 (pt) | 2008-08-04 | 2017-06-27 | Chdi Inc | pelo menos uma entidade química, composição farmacêutica, e, método para tratar uma condição ou distúrbio. |
| JP2013518046A (ja) | 2010-01-25 | 2013-05-20 | シーエイチディーアイ ファウンデーション，インコーポレーテッド | 特定のキヌレニン−３−モノオキシゲナーゼインヒビターおよびその医薬組成物ならびにこれらの使用方法 |
| AU2011217239B2 (en) | 2010-02-18 | 2014-06-12 | B.R.A.I.N. Biotechnology Research And Information Network Ag | Chimeric surface active proteins |
| JP2013540145A (ja) * | 2010-10-21 | 2013-10-31 | ウニベルシテート デス ザールランデス | コルチゾール依存性疾患の治療用の選択的ｃｙｐ１１ｂ１阻害剤 |
| CA2844128C (en) | 2011-08-30 | 2020-09-01 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
| BR112014004845A2 (pt) | 2011-08-30 | 2017-04-04 | Chdi Foundation Inc | pelo menos uma entidade química; pelo menos um composto; composição farmacêutica; uso de uma quantidade terapeuticamente eficaz de pelo menos uma entidade química; composição farmacêutica embalada |
| US8809372B2 (en) | 2011-09-30 | 2014-08-19 | Asana Biosciences, Llc | Pyridine derivatives |
| CA2850508A1 (en) * | 2011-09-30 | 2013-04-04 | Endo Pharmaceuticals Inc. | Imidazole derivatives as cyp17 inhibitors for the treatment of cancer |
| US9199975B2 (en) | 2011-09-30 | 2015-12-01 | Asana Biosciences, Llc | Biaryl imidazole derivatives for regulating CYP17 |
| SG11201700341PA (en) | 2014-07-17 | 2017-02-27 | Chdi Foundation Inc | Methods and compositions for treating hiv-related disorders |
| USRE49517E1 (en) | 2014-08-15 | 2023-05-02 | Janssen Pharmaceuticals, Inc. | Pyrazoles |
| PL3180329T3 (pl) * | 2014-08-15 | 2020-08-24 | Janssen Pharmaceuticals, Inc. | Triazole jako inhibitory receptora NR2B |
| DE102015011861B4 (de) | 2015-09-10 | 2018-03-01 | Rudolf Schindler | Neue cyclische Carboxamide als NMDA NR2B Rezeptor Inhibitoren |
| WO2017139428A1 (en) | 2016-02-10 | 2017-08-17 | Janssen Pharmaceutica Nv | Substituted 1,2,3-triazoles as nr2b-selective nmda modulators |
| TW201819376A (zh) | 2016-10-06 | 2018-06-01 | 比利時商健生藥品公司 | 經取代之１Ｈ－咪唑並［４，５－ｂ］吡啶－２（３Ｈ）－酮及其作為ＧＬＵＮ２Ｂ受體調節劑之用途 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| TWI827583B (zh) | 2018-03-08 | 2024-01-01 | 美商英塞特公司 | 作為ＰＩ３Ｋ-γ抑制劑之胺基吡嗪二醇化合物 |
| EP3774732A4 (en) | 2018-04-04 | 2022-02-09 | Janssen Pharmaceutica NV | PYRIDINE AND SUBSTITUTED PYRIMIDINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS |
| WO2020010003A1 (en) | 2018-07-02 | 2020-01-09 | Incyte Corporation | AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS |
| JP7667097B2 (ja) | 2019-06-14 | 2025-04-22 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロ－ピリジンアミド及びｇｌｕｎ２ｂ受容体調節因子としてのその使用 |
| CA3143103A1 (en) | 2019-06-14 | 2020-12-17 | Janssen Pharmaceutica Nv | Pyridine carbamates and their use as glun2b receptor modulators |
| KR20220020915A (ko) | 2019-06-14 | 2022-02-21 | 얀센 파마슈티카 엔.브이. | GluN2B 수용체 조절제로서의 피라진 카르바메이트 및 이들의 용도 |
| JP2022536773A (ja) | 2019-06-14 | 2022-08-18 | ヤンセン ファーマシューティカ エヌ．ベー． | 置換ピラゾロピラジン及びｇｌｕｎ２ｂ受容体調節因子としてのそれらの使用 |
| CN114007610A (zh) | 2019-06-14 | 2022-02-01 | 詹森药业有限公司 | 取代的杂芳族吡唑并吡啶以及它们作为glun2b受体调节剂的用途 |
| MA56196A (fr) | 2019-06-14 | 2022-04-20 | Janssen Pharmaceutica Nv | Pyrazolo-pyridine amides substitués et leur utilisation en tant que modulateurs du récepteur glun2b |
| MX2021015510A (es) | 2019-06-14 | 2022-04-11 | Janssen Pharmaceutica Nv | Pirazolo[4,3-b]piridinas sustituidas y su uso como moduladores del receptor glun2b. |
| CN115656401B (zh) * | 2022-11-09 | 2025-03-28 | 武汉海特生物创新医药研究有限公司 | 一种咪唑-4-甲酸乙酯纯度的hplc检测方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3627155A1 (de) | 1986-08-11 | 1988-02-18 | Schering Ag | Imidazol-derivate |
| CN1040107C (zh) * | 1993-01-02 | 1998-10-07 | 山道士有限公司 | 咪唑基甲基吡啶 |
| US5872136A (en) * | 1996-04-03 | 1999-02-16 | Merck & Co., Inc. | Arylheteroaryl inhibitors of farnesyl-protein transferase |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| IT1300055B1 (it) | 1998-04-17 | 2000-04-05 | Boehringer Ingelheim Italia | Eterocicli con anello a 5 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmici |
| DK1070708T3 (da) | 1999-07-21 | 2004-05-10 | Hoffmann La Roche | Triazolderivater |
-
2001
- 2001-12-20 US US10/029,342 patent/US6610723B2/en not_active Expired - Lifetime
-
2002
- 2002-01-21 KR KR1020037009992A patent/KR100619106B1/ko not_active Expired - Fee Related
- 2002-01-21 CN CN2010101215002A patent/CN101798298B/zh not_active Expired - Fee Related
- 2002-01-21 DE DE60231477T patent/DE60231477D1/de not_active Expired - Lifetime
- 2002-01-21 EP EP02714095A patent/EP1358165B1/en not_active Expired - Lifetime
- 2002-01-21 DK DK02714095T patent/DK1358165T3/da active
- 2002-01-21 JP JP2002561027A patent/JP4094956B2/ja not_active Expired - Fee Related
- 2002-01-21 MX MXPA03006773A patent/MXPA03006773A/es active IP Right Grant
- 2002-01-21 AT AT02714095T patent/ATE425147T1/de active
- 2002-01-21 ES ES02714095T patent/ES2319967T3/es not_active Expired - Lifetime
- 2002-01-21 WO PCT/EP2002/000552 patent/WO2002060877A1/en not_active Ceased
- 2002-01-21 PT PT02714095T patent/PT1358165E/pt unknown
- 2002-01-21 CN CN028042557A patent/CN1489580B/zh not_active Expired - Fee Related
- 2002-01-21 CA CA002434813A patent/CA2434813C/en not_active Expired - Fee Related
- 2002-01-21 BR BR0206758-7A patent/BR0206758A/pt not_active IP Right Cessation
- 2002-01-24 PE PE2002000055A patent/PE20020917A1/es not_active Application Discontinuation
- 2002-01-24 PA PA20028537801A patent/PA8537801A1/es unknown
- 2002-01-25 AR ARP020100261A patent/AR035422A1/es not_active Application Discontinuation
- 2002-01-25 MY MYPI20020294A patent/MY138334A/en unknown
- 2002-01-28 GC GCP20021833 patent/GC0000318A/en active
- 2002-01-28 GT GT200200013A patent/GT200200013A/es unknown
- 2002-01-29 JO JO20029A patent/JO2292B1/en active
-
2003
- 2003-02-11 US US10/364,596 patent/US6683097B2/en not_active Expired - Lifetime
- 2003-02-13 US US10/365,995 patent/US6667335B2/en not_active Expired - Lifetime
- 2003-07-21 ZA ZA200305626A patent/ZA200305626B/en unknown
-
2009
- 2009-05-15 CY CY20091100522T patent/CY1110265T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY138334A (en) | Imidazole derivatives | |
| EP1026950A4 (en) | Treatment of schizophrenia with ampakines and neuroleptics | |
| TNSN05045A1 (en) | Indole or benzimidazole derivatives for modulating ikappab kinase | |
| MA30392B1 (fr) | Composes organiques et leurs utilisations | |
| ATE466002T1 (de) | Substituierte benzo (d) isoaxol-3-yl-amin- verbindungen als analgetika | |
| NO20054407L (no) | Cannabinoid reseptor ligander og deres anvendelser | |
| AU1816901A (en) | Benzimidazole compounds having nociceptin receptor affinity | |
| YU91002A (sh) | Derivati acilfenil-karbamida, postupak za njihovu proizvodnju i njihova primena kao leka | |
| MX2009004060A (es) | Moduladores de proteina cinasa de triazolpiridazina. | |
| MY145070A (en) | Imidazolothiazole compounds for the treatment of disease | |
| CA2620129C (en) | Diaminopyrimidines as p2x3 and p2x2/3 modulators | |
| NZ544244A (en) | Dual NK1/NK3 antagonists for treating schizophrenia | |
| WO2004037342A3 (en) | Electrical stimulation of the brain | |
| IL165505A0 (en) | 2-heteroaryl carboxamides | |
| ATE484506T1 (de) | Substituierte diazepin-sulfonamide als bombesin- rezeptor-subtyp-3-modulatoren | |
| WO2002073196A3 (en) | Individualization of therapy with antipsychotics | |
| NO20032406D0 (no) | Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens | |
| HRP20040186B1 (en) | Use of lhrh-antagonists for the improvement of t-cell mediated immunity | |
| NO20051663L (no) | Fremgangsmater for behandling av neurodegenerasjon | |
| DK1368023T3 (da) | Anvendelse af buprenoprphin til behandling af urininkontinens | |
| MXPA04001855A (es) | Derivados de sistemas de indan-1-ol c2-sustituidos, metodos para la produccion de los mismos y su uso como medicamentos. | |
| NO20032411L (no) | Anvendelse av substituerte 6-dimetylaminometyl-1-fenyl- cykloheksan-forbindelser for behandling av urininkontinens | |
| MY127328A (en) | 5-amino-1-pentene-3-ol substituted derivatives | |
| SI1581227T1 (sl) | Metoda za zdravljenje odpovedi ledvic | |
| NO20024545D0 (no) | Fremgangsmåte for behandling av kongestiv hjertefeil |